source
- Biogen pushing tau drug forward despite Alzheimer’s study failureOne of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
- In vivo CAR-T therapies dominate talks at ASGCT 2026 conferenceThe reporter is on the ground in Boston covering the American Society of Gene & Cell Therapy's annual meeting. Sessions across the conference are highlighting in vivo CAR-T approaches, showing tha…